Bio-Rad Laboratories, Inc. (BIO) Quick Ratio (Acid-Test): 4.19
Is Bio-Rad Laboratories, Inc.’s quick ratio (acid-test) high or low?
Bio-Rad Laboratories, Inc.'s quick ratio (acid-test) of 4.19 is 13% above its 5-year average of 3.69, near the high end of its 5-year range (2.08–4.85).
The quick ratio (acid-test) for Bio-Rad Laboratories, Inc. (BIO) is 4.19 as of Tuesday, June 9, 2026. It is below its 12-month average by 7.30% (4.52).
BIO Quick Ratio (Acid-Test) Chart
BIO Average Quick Ratio (Acid-Test) Chart
BIO Current vs Average Quick Ratio (Acid-Test) Chart
BIO Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
4.19
QUICK RATIO (ACID-TEST) AVG TTM
4.52
QUICK RATIO (ACID-TEST) AVG 3Y
4.42
QUICK RATIO (ACID-TEST) AVG 5Y
3.69
QUICK RATIO (ACID-TEST) AVG 10Y
3.24
QUICK RATIO (ACID-TEST) AVG 15Y
3.09
QUICK RATIO (ACID-TEST) AVG 20Y
2.90
CURRENT VS TTM AVG
-7.30%
CURRENT VS 3Y AVG
-5.15%
CURRENT VS 5Y AVG
+13.50%
CURRENT VS 10Y AVG
+29.43%
CURRENT VS 15Y AVG
+35.63%
CURRENT VS 20Y AVG
+44.32%
BIO Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | — | 4.19 | 4.52 | 4.42 | 3.69 |
| Charles River Laboratories International, Inc. (CRL) | $9.14B | 1.02 | 1.07 | 1.10 | 1.11 |
| Hims & Hers Health, Inc. (HIMS) | $6.46B | 1.61 | 1.56 | 2.48 | 3.39 |
| Align Technology, Inc. (ALGN) | $12.76B | 1.24 | 1.17 | 1.11 | 1.16 |
| Hologic, Inc. (HOLX) | $16.97B | 3.06 | 3.04 | 3.12 | 2.66 |
| Moderna, Inc. (MRNA) | $18.94B | 3.22 | 3.42 | 3.19 | 2.63 |
| BioNTech SE (BNTX) | $21.87B | 7.49 | 7.42 | 7.84 | 6.36 |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 0.81 | 0.77 | 0.77 | 0.79 |
| Waters Corporation (WAT) | $24.19B | 1.27 | 1.39 | 1.50 | 1.54 |
| Veeva Systems Inc. (VEEV) | $27.37B | 4.89 | 4.70 | 4.39 | 4.08 |
Liquidity Comparison
Quick Ratio
4.19
Excludes inventory
Current Ratio
5.62
Includes inventory
Bio-Rad Laboratories, Inc. Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Bio-Rad Laboratories, Inc. (BIO)?
- The quick ratio (acid-test) for BIO stock is 4.19.
- Is Bio-Rad Laboratories, Inc.'s quick ratio (acid-test) high or low?
- Bio-Rad Laboratories, Inc.'s quick ratio (acid-test) of 4.19 is 13% above its 5-year average of 3.69, near the high end of its 5-year range (2.08–4.85).
- What is the TTM average quick ratio (acid-test) for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average quick ratio (acid-test) for BIO stock is 4.52.
- What is the 3Y average quick ratio (acid-test) for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average quick ratio (acid-test) for BIO stock is 4.42.
- What is the 5Y average quick ratio (acid-test) for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average quick ratio (acid-test) for BIO stock is 3.69.
- What is the 10Y average quick ratio (acid-test) for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average quick ratio (acid-test) for BIO stock is 3.24.
- What is the 15Y average quick ratio (acid-test) for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average quick ratio (acid-test) for BIO stock is 3.09.
- What is the 20Y average quick ratio (acid-test) for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average quick ratio (acid-test) for BIO stock is 2.90.
Bio-Rad Laboratories, Inc. Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 4.19 |
| 2024-12-31 | 4.85 |
| 2023-12-31 | 4.34 |
| 2022-12-31 | 4.29 |
| 2021-12-31 | 2.08 |
| 2020-12-31 | 2.40 |
| 2019-12-31 | 1.80 |
| 2018-12-31 | 3.19 |
| 2017-12-31 | 2.75 |
| 2016-12-31 | 2.80 |
| 2015-12-31 | 2.92 |
| 2014-12-31 | 2.79 |
| 2013-12-31 | 2.55 |
| 2012-12-31 | 3.14 |
| 2011-12-31 | 2.97 |
| 2010-12-31 | 2.37 |
| 2009-12-31 | 2.88 |
| 2008-12-31 | 1.72 |
| 2007-12-31 | 1.71 |
| 2006-12-31 | 2.74 |
| 2005-12-31 | 2.49 |
| 2004-12-31 | 2.23 |
| 2003-12-31 | 1.94 |
| 2002-12-31 | 1.35 |
| 2001-12-31 | 1.46 |
| 2000-12-31 | 1.25 |
| 1999-12-31 | 1.25 |
| 1998-12-31 | 1.47 |
| 1997-12-31 | 1.35 |
| 1996-12-31 | 1.63 |
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz